González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962.
Article
PubMed
Google Scholar
Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, et al. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2020;146(2):439–48. https://doi.org/10.1002/ijc.32606.
Article
CAS
PubMed
Google Scholar
Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? J Gynecol Oncol. 2019;30(5): e81. https://doi.org/10.3802/jgo.2019.30.e81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505. https://doi.org/10.1056/NEJMoa1810858.
Article
CAS
PubMed
Google Scholar
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–28. https://doi.org/10.1056/NEJMoa1911361.
Article
CAS
PubMed
Google Scholar
Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D’Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, et al. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Target Oncol. 2021;16(1):59–68. https://doi.org/10.1007/s11523-020-00780-4.
Article
PubMed
Google Scholar
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61. https://doi.org/10.1016/S0140-6736(17)32440-6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36. https://doi.org/10.1016/S1470-2045(15)00086-8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. https://doi.org/10.1056/NEJMoa1104390.
Article
CAS
PubMed
Google Scholar
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. https://doi.org/10.1056/NEJMoa1103799.
Article
CAS
PubMed
Google Scholar
du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–82. https://doi.org/10.1200/JCO.2014.55.7348.
Article
PubMed
Google Scholar
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30(4):551–7. https://doi.org/10.1093/annonc/mdz018.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–74. https://doi.org/10.1016/S0140-6736(15)01167-8.
Article
CAS
PubMed
Google Scholar
Vergote I, Scambia G, O’Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(6):862–76. https://doi.org/10.1016/S1470-2045(19)30178-0.
Article
CAS
PubMed
Google Scholar
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv259. https://doi.org/10.1093/annonc/mdy157.
Article
CAS
PubMed
Google Scholar
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019;381(25):2403–15. https://doi.org/10.1056/NEJMoa1909707.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017;35(10):1103–11. https://doi.org/10.1200/JCO.2016.71.0632.
Article
PubMed
PubMed Central
Google Scholar
Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012;125(3):661–6. https://doi.org/10.1016/j.ygyno.2012.02.037.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kitawaki J, Noguchi T, Yamamoto T, Yokota K, Maeda K, Urabe M, Honjo H. Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Anticancer Res. 1996;16(1):91–7.
CAS
PubMed
Google Scholar
Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;2009(4):CD003370. https://doi.org/10.1002/14651858.CD003370.
Article
PubMed Central
Google Scholar
Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, Cruz JM, Jackson DV Jr, O’Rourke MA, Pavy MD, Powell BL, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994;12(8):1630–8. https://doi.org/10.1200/JCO.1994.12.8.1630.
Article
CAS
PubMed
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52. https://doi.org/10.1016/S0140-6736(15)61074-1.
Article
CAS
Google Scholar
Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer. 2004;90(1):20–5. https://doi.org/10.1038/sj.bjc.6601508.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sasano H, Sato S, Ito K, Yajima A, Nakamura J, Yoshihama M, Ariga K, Anderson TJ, Miller WR. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer. 1999;6(2):197–204. https://doi.org/10.1677/erc.0.0060197.
Article
CAS
PubMed
Google Scholar
Langdon SP, Gourley C, Gabra H, Stanley B. Endocrine therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(2):109–17. https://doi.org/10.1080/14737140.2017.1272414.
Article
CAS
PubMed
Google Scholar
Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8(7):2233–9.
CAS
PubMed
Google Scholar
Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007;13(12):3617–22. https://doi.org/10.1158/1078-0432.CCR-06-2878.
Article
CAS
PubMed
Google Scholar
Heinzelmann-Schwarz V, Knipprath Mészaros A, Stadlmann S, Jacob F, Schoetzau A, Russell K, Friedlander M, Singer G, Vetter M. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecol Oncol. 2018;148(1):79–85. https://doi.org/10.1016/j.ygyno.2017.10.036.
Article
CAS
PubMed
Google Scholar
Knipprath- Mészaros A, Heinzelmann-Schwarz V, Vetter M. Endocrine Therapy in Epithelial Ovarian Cancer (EOC) New Insights in an Old Target. Mini Rev J Cancer Clin Trials. 2018;3:2. https://doi.org/10.4172/2577-0535.1000144.
Article
Google Scholar
Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont CR, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). Br J Cancer. 2017;116(4):455–63. https://doi.org/10.1038/bjc.2016.435.
Article
CAS
PubMed
PubMed Central
Google Scholar
Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(9):1134–63. https://doi.org/10.6004/jnccn.2016.0122.
Article
PubMed
Google Scholar
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, et al. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016;34(22):2602–9. https://doi.org/10.1200/JCO.2015.66.1595.
Article
CAS
PubMed
PubMed Central
Google Scholar
Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, et al. Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. Adv Ther. 2018;35(11):1945–64. https://doi.org/10.1007/s12325-018-0804-z.
Article
CAS
PubMed
Google Scholar
Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N, DeCensi A. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. Gynecol Oncol. 2017;146(3):504–13. https://doi.org/10.1016/j.ygyno.2017.06.036.
Article
PubMed
Google Scholar
Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk-Schulz IM, Jobsen JJ, Creutzberg CL, Smit VT. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer. 2014;50(15):2602–10. https://doi.org/10.1016/j.ejca.2014.07.014.
Article
CAS
PubMed
Google Scholar
Soovares P, Pasanen A, Bützow R, Lassus H. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecol Oncol. 2017;146(3):615–22. https://doi.org/10.1016/j.ygyno.2017.06.010.
Article
CAS
PubMed
Google Scholar
Tsoi M, Morin M, Rico C, Johnson RL, Paquet M, Gévry N, Boerboom D. Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance. FASEB J. 2019;33(10):10819–32. https://doi.org/10.1096/fj.201900609R.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu B, Sun D, Wang Z, Weng H, Wu D, Zhang X, Zhou Y, Hu W. Expression of LATS family proteins in ovarian tumors and its significance. Hum Pathol. 2015;46(6):858–67. https://doi.org/10.1016/j.humpath.2015.02.012.
Article
CAS
PubMed
Google Scholar
Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011;24(3):453–62. https://doi.org/10.1038/modpathol.2010.211.
Article
CAS
PubMed
Google Scholar
Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, et al. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol. 2019;154(1):199–206. https://doi.org/10.1016/j.ygyno.2019.04.010.
Article
CAS
PubMed
Google Scholar
Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open. 2019;4(2): e000444.
Article
Google Scholar
Jacob F, Alam S, Konantz M, Liang CY, Kohler RS, Everest-Dass AV, Huang YL, Rimmer N, Fedier A, Schötzau A, et al. Transition of Mesenchymal and Epithelial Cancer Cells Depends on α1-4 Galactosyltransferase-Mediated Glycosphingolipids. Cancer Res. 2018;78(11):2952–65. https://doi.org/10.1158/0008-5472.CAN-17-2223.
Article
CAS
PubMed
Google Scholar
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14. https://doi.org/10.1016/S1470-2045(14)70391-2.
Article
CAS
PubMed
PubMed Central
Google Scholar
Banerjee S. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Steroids. 2011;76(8):807–11. https://doi.org/10.1016/j.steroids.2011.02.036.
Article
CAS
PubMed
Google Scholar
Machin D, Campbell MJ, Tan SB, Tan SH. Sample Size Tables for Clinical Studies. Third Edition. 2009. https://doi.org/10.1002/9781444300710.
Article
Google Scholar
Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507–19.
Article
CAS
Google Scholar
Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409–21. https://doi.org/10.1002/sim.4274.
Article
PubMed
Google Scholar
Sabbatini P. Consolidation therapy in ovarian cancer: a clinical update. Int J Gynecol Cancer. 2009;19(Suppl 2):S35–9. https://doi.org/10.1111/IGC.0b013e3181c14007.
Article
PubMed
Google Scholar
Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853–62. https://doi.org/10.1016/S1470-2045(13)70253-5.
Article
CAS
PubMed
PubMed Central
Google Scholar